Other response observations have suggested potentially important biomarkers that are currently being assessed further (e.g., DDR2 mutations [75] and inactivating BRAF mutations [76] for dasatinib in NSCLC). The gene discussed is DDR2; the disease is non-small cell lung carcinoma.